TRACON Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TCON)

$2.20 -0.02 (-0.90 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$2.20
Today's Range$2.15 - $2.35
52-Week Range$2.00 - $4.70
Volume377,852 shs
Average Volume231,871 shs
Market Capitalization$38.96 million
P/E Ratio-1.80
Dividend YieldN/A
Beta2.06

About TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals logoTRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TCON
CUSIPN/A
Phone858-550-0780

Debt

Debt-to-Equity Ratio0.24%
Current Ratio3.80%
Quick Ratio3.80%

Price-To-Earnings

Trailing P/E Ratio-1.80326390767289
Forward P/E Ratio-1.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.45 million
Price / Sales11.17
Cash FlowN/A
Price / CashN/A
Book Value$1.76 per share
Price / Book1.25

Profitability

Trailing EPS($1.22)
Net Income$-27,000,000.00
Net Margins-201.21%
Return on Equity-83.43%
Return on Assets-49.01%

Miscellaneous

Employees27
Outstanding Shares17,510,000

TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals Inc (NASDAQ:TCON) issued its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.32. The biopharmaceutical company had revenue of $7.50 million for the quarter, compared to analyst estimates of $7.60 million. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 83.43%. View TRACON Pharmaceuticals' Earnings History.

When will TRACON Pharmaceuticals make its next earnings announcement?

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for TRACON Pharmaceuticals.

Where is TRACON Pharmaceuticals' stock going? Where will TRACON Pharmaceuticals' stock price be in 2018?

1 brokerages have issued 1-year price objectives for TRACON Pharmaceuticals' shares. Their predictions range from $6.00 to $6.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $6.00 in the next year. View Analyst Ratings for TRACON Pharmaceuticals.

Who are some of TRACON Pharmaceuticals' key competitors?

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the folowing people:

  • Charles P. Theuer, President, Chief Executive Officer, Director (Age 53)
  • Patricia L. Bitar CPA, Chief Financial Officer (Age 58)
  • H Casey Logan, Chief Business Officer (Age 45)
  • William R. LaRue, Independent Director (Age 66)
  • Martin A. Mattingly Ph.D., Independent Director (Age 60)
  • J. Rainer Twiford Ph.D., J.D., Independent Director (Age 64)
  • Paul Walker, Independent Director (Age 42)
  • Stephen T. Worland Ph.D., Independent Director (Age 59)

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Who owns TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (8.51%), Renaissance Technologies LLC (1.51%), X Square Capital LLC (0.74%) and QVT Financial LP (0.71%). Company insiders that own TRACON Pharmaceuticals stock include Peter W Sonsini, Ronald L Shazer and William R Larue. View Institutional Ownership Trends for TRACON Pharmaceuticals.

Who sold TRACON Pharmaceuticals stock? Who is selling TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including QVT Financial LP. View Insider Buying and Selling for TRACON Pharmaceuticals.

Who bought TRACON Pharmaceuticals stock? Who is buying TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, X Square Capital LLC and Renaissance Technologies LLC. View Insider Buying and Selling for TRACON Pharmaceuticals.

How do I buy TRACON Pharmaceuticals stock?

Shares of TRACON Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TRACON Pharmaceuticals' stock price today?

One share of TRACON Pharmaceuticals stock can currently be purchased for approximately $2.20.

How big of a company is TRACON Pharmaceuticals?

TRACON Pharmaceuticals has a market capitalization of $38.96 million and generates $3.45 million in revenue each year. The biopharmaceutical company earns $-27,000,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. TRACON Pharmaceuticals employs 27 workers across the globe.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 La Jolla Village Drive Suite 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]


MarketBeat Community Rating for TRACON Pharmaceuticals (TCON)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TRACON Pharmaceuticals (NASDAQ:TCON) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.672.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$8.00$8.00
Price Target Upside: 135.29% upside135.29% upside213.73% upside213.73% upside

TRACON Pharmaceuticals (NASDAQ:TCON) Consensus Price Target History

Price Target History for TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals (NASDAQ:TCON) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/13/2017Stifel NicolausLower Price TargetBuy -> Buy$14.00 -> $6.00HighView Rating Details
1/3/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
12/21/2016Jefferies GroupInitiated CoverageBuy$10.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$15.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

TRACON Pharmaceuticals (NASDAQ:TCON) Earnings History and Estimates Chart

Earnings by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals (NASDAQ TCON) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.46)N/AView Earnings Details
11/7/2017Q3 2017($0.25)$0.07$7.60 million$7.50 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.52)($0.40)$0.81 million$0.63 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.47)($0.44)$0.92 million$0.63 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.45)($0.45)$0.83 million$0.62 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.58)($0.48)$1.33 million$0.82 millionViewN/AView Earnings Details
8/10/2016Q2($0.62)($0.68)$1.27 million$0.81 millionViewListenView Earnings Details
5/11/2016Q1($0.70)($0.54)$1.21 millionViewListenView Earnings Details
2/18/2016Q4($0.62)($0.91)$1.40 millionViewListenView Earnings Details
11/3/2015Q3($0.51)($0.53)$1.06 million$1.18 millionViewListenView Earnings Details
8/5/2015Q215($0.42)($0.24)$1.02 million$4.20 millionViewListenView Earnings Details
5/13/2015Q1($0.37)($0.50)$1.13 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

TRACON Pharmaceuticals (NASDAQ:TCON) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.21 EPS
Next Year EPS Consensus Estimate: $-0.8 EPS

Dividends

Dividend History for TRACON Pharmaceuticals (NASDAQ:TCON)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

TRACON Pharmaceuticals (NASDAQ TCON) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 34.08%
Insider Trades by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Institutional Ownership by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals (NASDAQ TCON) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2017William R LarueDirectorSell2,500$2.69$6,725.0013,388View SEC Filing  
11/29/2016Peter W SonsiniMajor ShareholderBuy869,565$5.75$4,999,998.75View SEC Filing  
6/3/2016Ronald L ShazerInsiderSell1,003$7.48$7,502.44335View SEC Filing  
10/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell1,500$9.90$14,850.001,497,053View SEC Filing  
10/15/2015Jafco Super V3 Investment LimiMajor ShareholderSell5,300$10.16$53,848.001,498,553View SEC Filing  
10/13/2015Jafco Super V3 Investment Limimajor shareholderSell3,168$10.01$31,711.681,503,853View SEC Filing  
10/9/2015Jafco Super V3 Investment Limimajor shareholderSell1,448$10.01$14,494.481,503,853View SEC Filing  
10/8/2015Jafco Super V3 Investment Limimajor shareholderSell21,920$10.10$221,392.001,507,021View SEC Filing  
10/5/2015Jafco Super V3 Investment Limimajor shareholderSell15,100$10.08$152,208.001,528,941View SEC Filing  
9/25/2015Jafco Super V3 Investment LimiMajor ShareholderSell7,600$12.13$92,188.001,544,041View SEC Filing  
9/24/2015Jafco Super V3 Investment Limimajor shareholderSell22,303$12.99$289,715.971,551,641View SEC Filing  
9/22/2015Jafco Super V3 Investment Limimajor shareholderSell39,426$14.02$552,752.521,573,944View SEC Filing  
9/21/2015Jafco Super V3 Investment Limimajor shareholderSell18,200$14.48$263,536.001,573,944View SEC Filing  
9/18/2015Charles TheuerCEOSell10,000$17.34$173,400.00View SEC Filing  
9/18/2015H Casey LoganinsiderSell5,000$17.34$86,700.00View SEC Filing  
9/17/2015Jafco Super V3 Investment Limimajor shareholderSell42,344$11.78$498,812.321,613,370View SEC Filing  
9/14/2015Jafco Super V3 Investment Limimajor shareholderSell60,038$11.78$707,247.641,655,714View SEC Filing  
9/10/2015Charles TheuerCEOSell3,516$12.00$42,192.00View SEC Filing  
9/9/2015Jafco Super V3 Investment Limimajor shareholderSell12,000$10.71$128,520.001,715,752View SEC Filing  
9/8/2015Jafco Super V3 Investment Limimajor shareholderSell5,700$10.47$59,679.001,715,752View SEC Filing  
9/4/2015Jafco Super V3 Investment Limimajor shareholderSell6,600$10.48$69,168.001,715,752View SEC Filing  
9/3/2015Jafco Super V3 Investment Limimajor shareholderSell15,300$10.51$160,803.001,740,052View SEC Filing  
9/1/2015Jafco Super V3 Investment Limimajor shareholderSell14,000$10.42$145,880.001,755,352View SEC Filing  
8/24/2015Jafco Super V3 Investment LimiMajor ShareholderSell3,000$11.00$33,000.001,769,352View SEC Filing  
8/20/2015Jafco Super V3 Investment Limimajor shareholderSell10,683$11.36$121,358.881,772,352View SEC Filing  
8/18/2015Jafco Super V3 Investment LimiMajor ShareholderSell11,174$11.71$130,847.54View SEC Filing  
8/13/2015Jafco Super V3 Investment LimiMajor ShareholderSell9,361$11.60$108,587.60View SEC Filing  
2/4/2015M James BarrettMajor ShareholderBuy500,000$10.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TRACON Pharmaceuticals (NASDAQ TCON) News Headlines

Source:
DateHeadline
 Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $710,000.00 Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $710,000.00
www.americanbankingnews.com - February 6 at 10:12 AM
TRACON Pharmaceuticals Inc (TCON) Expected to Announce Earnings of -$0.45 Per ShareTRACON Pharmaceuticals Inc (TCON) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - February 4 at 3:18 AM
$710,000.00 in Sales Expected for TRACON Pharmaceuticals Inc (TCON) This Quarter$710,000.00 in Sales Expected for TRACON Pharmaceuticals Inc (TCON) This Quarter
www.americanbankingnews.com - January 20 at 2:32 PM
TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma PatientsTRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients
finance.yahoo.com - January 19 at 3:44 PM
TRACON Pharmaceuticals Reports Granting of Inducement AwardsTRACON Pharmaceuticals Reports Granting of Inducement Awards
finance.yahoo.com - January 18 at 6:17 PM
 Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - January 18 at 5:08 AM
Financial Analysis: TRACON Pharmaceuticals (TCON) & Its PeersFinancial Analysis: TRACON Pharmaceuticals (TCON) & Its Peers
www.americanbankingnews.com - January 11 at 8:18 AM
TRACON Pharmaceuticals (TCON) Downgraded by Zacks Investment ResearchTRACON Pharmaceuticals (TCON) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 5 at 12:32 PM
Critical Survey: TRACON Pharmaceuticals (TCON) vs. Its RivalsCritical Survey: TRACON Pharmaceuticals (TCON) vs. Its Rivals
www.americanbankingnews.com - January 3 at 10:14 AM
ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 27, 2017ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 1:07 PM
TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 12:44 PM
Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in ChinaAmbrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China
www.bizjournals.com - December 21 at 3:39 PM
TRACON Pharmaceuticals and Ambrx Announce Development and ... - GlobeNewswire (press release)TRACON Pharmaceuticals and Ambrx Announce Development and ... - GlobeNewswire (press release)
www.globenewswire.com - December 21 at 11:32 AM
35 Stocks Moving In Thursdays Pre-Market Session - Benzinga35 Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - December 21 at 11:32 AM
TRACON Pharmaceuticals (TCON) and Ambrx Enter Pact for ... - StreetInsider.comTRACON Pharmaceuticals (TCON) and Ambrx Enter Pact for ... - StreetInsider.com
www.streetinsider.com - December 21 at 11:32 AM
TRACON Pharmaceuticals and Ambrx Announce Development and Commercialization Agreement for TRC105 in ChinaTRACON Pharmaceuticals and Ambrx Announce Development and Commercialization Agreement for TRC105 in China
finance.yahoo.com - December 21 at 11:32 AM
Contrasting TRACON Pharmaceuticals (TCON) and Its RivalsContrasting TRACON Pharmaceuticals (TCON) and Its Rivals
www.americanbankingnews.com - December 18 at 3:28 AM
$710,000.00 in Sales Expected for TRACON Pharmaceuticals, Inc. (TCON) This Quarter$710,000.00 in Sales Expected for TRACON Pharmaceuticals, Inc. (TCON) This Quarter
www.americanbankingnews.com - December 17 at 4:30 AM
TRACON Pharmaceuticals Announces Appointment of Brian Daniels, MD, to Scientific Advisory Board - GlobeNewswire (press release)TRACON Pharmaceuticals Announces Appointment of Brian Daniels, MD, to Scientific Advisory Board - GlobeNewswire (press release)
globenewswire.com - December 5 at 12:04 PM
TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory BoardTRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board
finance.yahoo.com - December 5 at 12:04 PM
TRACON Doses First Patient in Phase 1b Study of TRC105 with Opdivo® in Patients with Lung CancerTRACON Doses First Patient in Phase 1b Study of TRC105 with Opdivo® in Patients with Lung Cancer
finance.yahoo.com - November 30 at 11:49 AM
Zacks: Analysts Anticipate TRACON Pharmaceuticals, Inc. (TCON) Will Post Quarterly Sales of $710,000.00Zacks: Analysts Anticipate TRACON Pharmaceuticals, Inc. (TCON) Will Post Quarterly Sales of $710,000.00
www.americanbankingnews.com - November 29 at 8:44 AM
TRACON Pharmaceuticals, Inc. (TCON) Expected to Post Quarterly Sales of $710,000.00TRACON Pharmaceuticals, Inc. (TCON) Expected to Post Quarterly Sales of $710,000.00
www.americanbankingnews.com - November 29 at 6:50 AM
TRACON Pharmaceuticals, Inc. (TCON) Expected to Announce Earnings of -$0.45 Per ShareTRACON Pharmaceuticals, Inc. (TCON) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - November 27 at 9:14 AM
TRACON Pharmaceuticals, Inc. (TCON) Expected to Post Earnings of -$0.45 Per ShareTRACON Pharmaceuticals, Inc. (TCON) Expected to Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - November 27 at 9:14 AM
34 Stocks Moving In Tuesdays Pre-Market Session - Benzinga34 Stocks Moving In Tuesday's Pre-Market Session - Benzinga
www.benzinga.com - November 14 at 3:47 PM
8 Stocks To Watch For November 14, 2017 | Benzinga - Benzinga8 Stocks To Watch For November 14, 2017 | Benzinga - Benzinga
www.benzinga.com - November 14 at 3:47 PM
FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz - NasdaqFDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz - Nasdaq
www.nasdaq.com - November 14 at 3:47 PM
Overall response rate of 24% seen with no dose limiting toxicity observedOverall response rate of 24% seen with no dose limiting toxicity observed
globenewswire.com - November 14 at 9:05 AM
TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in OncotargetTRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget
finance.yahoo.com - November 14 at 9:05 AM
Tracon Pharmaceuticals (TCON) CEO Charles Theuer on Q3 2017 ... - Seeking AlphaTracon Pharmaceuticals' (TCON) CEO Charles Theuer on Q3 2017 ... - Seeking Alpha
seekingalpha.com - November 11 at 7:26 PM
TRACON Pharmaceuticals, Inc. (TCON) Upgraded by Zacks Investment Research to "Buy"TRACON Pharmaceuticals, Inc. (TCON) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - November 11 at 8:10 AM
Brokers Set Expectations for TRACON Pharmaceuticals, Inc.s FY2017 Earnings (TCON)Brokers Set Expectations for TRACON Pharmaceuticals, Inc.'s FY2017 Earnings (TCON)
www.americanbankingnews.com - November 10 at 12:55 PM
$790,000.00 in Sales Expected for TRACON Pharmaceuticals, Inc. (TCON) This Quarter$790,000.00 in Sales Expected for TRACON Pharmaceuticals, Inc. (TCON) This Quarter
www.americanbankingnews.com - November 10 at 4:24 AM
TRACON Pharmaceutical (TCON) Reports Updated Data on Phase 1b/2 Study of TRC105 and Votrient - StreetInsider.comTRACON Pharmaceutical (TCON) Reports Updated Data on Phase 1b/2 Study of TRC105 and Votrient - StreetInsider.com
www.streetinsider.com - November 9 at 2:37 PM
TRACON Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 2:36 PM
Tracon beats 3Q profit forecastsTracon beats 3Q profit forecasts
finance.yahoo.com - November 9 at 2:36 PM
TRACON Pharmaceuticals Presents Updated Data from Phase 1b/2 Study of TRC105 and Votrient® in Patients with Soft Tissue Sarcoma Including AngiosarcomaTRACON Pharmaceuticals Presents Updated Data from Phase 1b/2 Study of TRC105 and Votrient® in Patients with Soft Tissue Sarcoma Including Angiosarcoma
finance.yahoo.com - November 9 at 2:36 PM
Edited Transcript of TCON earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of TCON earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 2:36 PM
Zacks: Analysts Anticipate TRACON Pharmaceuticals, Inc. (TCON) to Post -$0.47 EPSZacks: Analysts Anticipate TRACON Pharmaceuticals, Inc. (TCON) to Post -$0.47 EPS
www.americanbankingnews.com - November 8 at 9:32 PM
TRACON Pharmaceuticals, Inc. (TCON) Posts  Earnings Results, Beats Expectations By $0.32 EPSTRACON Pharmaceuticals, Inc. (TCON) Posts Earnings Results, Beats Expectations By $0.32 EPS
www.americanbankingnews.com - November 8 at 4:23 PM
TRACON Pharmaceuticals to Present at Upcoming Investment Conferences - GlobeNewswire (press release)TRACON Pharmaceuticals to Present at Upcoming Investment Conferences - GlobeNewswire (press release)
globenewswire.com - November 7 at 11:44 AM
TRACON Pharmaceuticals to Present at Upcoming Investment ConferencesTRACON Pharmaceuticals to Present at Upcoming Investment Conferences
finance.yahoo.com - November 7 at 11:44 AM
TRACON Pharmaceuticals, Inc. to Host Earnings CallTRACON Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 11:44 AM
TRACON to Report Third Quarter Company Highlights and Financial Results on November 7, 2017TRACON to Report Third Quarter Company Highlights and Financial Results on November 7, 2017
finance.yahoo.com - October 31 at 8:44 PM
TRACON Pharmaceuticals, Inc. (TCON) Scheduled to Post Quarterly Earnings on MondayTRACON Pharmaceuticals, Inc. (TCON) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:36 AM
ETFs with exposure to TRACON Pharmaceuticals, Inc. : October 23, 2017ETFs with exposure to TRACON Pharmaceuticals, Inc. : October 23, 2017
finance.yahoo.com - October 24 at 10:59 AM
 Brokerages Anticipate TRACON Pharmaceuticals, Inc. (TCON) Will Announce Quarterly Sales of $7.60 Million Brokerages Anticipate TRACON Pharmaceuticals, Inc. (TCON) Will Announce Quarterly Sales of $7.60 Million
www.americanbankingnews.com - October 22 at 1:40 PM
TRACON Pharmaceuticals Announces Multiple TRC105 Poster ... - GlobeNewswire (press release)TRACON Pharmaceuticals Announces Multiple TRC105 Poster ... - GlobeNewswire (press release)
globenewswire.com - October 17 at 7:54 AM
TRACON Pharmaceuticals Announces Multiple TRC105 Poster Presentations at 18th IASLC World Conference on Lung CancerTRACON Pharmaceuticals Announces Multiple TRC105 Poster Presentations at 18th IASLC World Conference on Lung Cancer
finance.yahoo.com - October 16 at 7:01 AM

SEC Filings

TRACON Pharmaceuticals (NASDAQ:TCON) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TRACON Pharmaceuticals (NASDAQ:TCON) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TRACON Pharmaceuticals (NASDAQ TCON) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.